Results 251 to 260 of about 106,281 (309)

Mecapegfilgrastim for Prophylaxis of Immunochemotherapy‐Induced Neutropenia in Patients With Diffuse Large B‐Cell Lymphoma: A Multicenter Pilot Trial

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy‐induced neutropenia in treatment‐naive patients with diffuse large B‐cell lymphoma (DLBCL). Methods In this open‐label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no ...
Jie Wang   +15 more
wiley   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang   +19 more
wiley   +1 more source

An XGBoost‐Based Multicenter Model for Predicting HBV‐Related Hepatocellular Carcinoma: Development and Validation

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
We developed a web‐based interactive tool to estimate individualized HCC risk in chronic HBV patients, enabling clinicians to input real‐time data for personalized risk probabilities and evidence‐based actionable recommendations. ABSTRACT Background The 5‐year survival rate for hepatocellular carcinoma (HCC) is stage‐dependent, yet existing models lack
Yong Lin   +7 more
wiley   +1 more source

Laboratory Data Analysis of Hemorrhagic Fever With Renal Syndrome Patients to Predict Disease Severity and Patient Prognosis. [PDF]

open access: yesJ Clin Lab Anal
Shi H   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy